Literature DB >> 2176506

Molecular-mechanics modelling of drug-DNA structures; the effects of differing dielectric treatment on helix parameters and comparison with a fully solvated structural model.

M Orozco1, C A Laughton, P Herzyk, S Neidle.   

Abstract

This study analyses the influence that the nature of the dielectric constant has on the final structures obtained from in vacuo molecular mechanics calculations on a drug-DNA complex and compares these structures with the energy minimised complex including explicit solvent molecules. Minimisations have been performed on a proflavine-decanucleotide structure, where the drug was intercalated at the d(CpG) site of the d(GpApTpApCpGpApTpApC) decamer duplex, using two expressions for the dielectric constant: a distance-independent, epsilon ij = EPS, and a distance-dependent, epsilon ij = EPS*Rij, form and for values of EPS from 1 to 8. Significantly different structures are obtained for the distance-independent and the distance-dependent expressions of the dielectric constant. The use of a distance-independent dielectric constant leads to distorted structures, which are very sensitive to slight changes in the value of EPS. The use of a distance-dependent dielectric constant leads to less distorted and more stable structures. The effects on helical parameters are analysed in detail. The structures obtained for different values of EPS (within the distance-dependent formalism) seem to converge for values of EPS equal to 4 or greater. Based on these results a distance-dependent form of the dielectric with an EPS value of 4 is recommended in order to produce reliable refined nucleic acid structures by molecular mechanics. These conclusions have been supported by molecular-mechanics minimisation of the same structure with the inclusion of explicit water molecules and counter-ions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176506     DOI: 10.1080/07391102.1990.10507810

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  8 in total

1.  3D-QSAR and molecular modeling of HIV-1 integrase inhibitors.

Authors:  Mahindra T Makhija; Vithal M Kulkarni
Journal:  J Comput Aided Mol Des       Date:  2002-03       Impact factor: 3.686

2.  Analysis of (1)H chemical shifts in DNA: Assessment of the reliability of (1)H chemical shift calculations for use in structure refinement.

Authors:  S S Wijmenga; M Kruithof; C W Hilbers
Journal:  J Biomol NMR       Date:  1997-12       Impact factor: 2.835

3.  Efficient triple helix formation by oligodeoxyribonucleotides containing alpha- or beta-2-amino-5-(2-deoxy-D-ribofuranosyl) pyridine residues.

Authors:  P J Bates; C A Laughton; T C Jenkins; D C Capaldi; P D Roselt; C B Reese; S Neidle
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

4.  N.m.r. determination of the solution conformation and dynamics of the A.G mismatch in the d(CGCAAATTGGCG)2 dodecamer.

Authors:  A N Lane; T C Jenkins; D J Brown; T Brown
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

5.  Human topoisomerase I C-terminal domain fragment containing the active site tyrosine is a molten globule: implication for the formation of competent productive complex.

Authors:  Chandanamali Punchihewa; Jixun Dai; Megan Carver; Danzhou Yang
Journal:  J Struct Biol       Date:  2007-03-12       Impact factor: 2.867

6.  Hydrogen bond geometry in DNA-minor groove binding drug complexes.

Authors:  L Tabernero; J Bella; C Alemán
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

7.  Prediction of the structure of the Y+.R-.R(+)-type DNA triple helix by molecular modelling.

Authors:  C A Laughton; S Neidle
Journal:  Nucleic Acids Res       Date:  1992-12-25       Impact factor: 16.971

8.  Probing the relationship between anti-Pneumocystis carinii activity and DNA binding of bisamidines by molecular dynamics simulations.

Authors:  Teresa Żołek; Dorota Maciejewska; Jerzy Żabiński; Paweł Kaźmierczak; Mateusz Rezler
Journal:  Molecules       Date:  2015-04-03       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.